Pharmaceuticals DC $500K+ Reviewed

Barda Drive Ez-baa (ezbaa - 22-100-sol-00003)

HHS

WASHINGTON, DC

vaccines on demand host-directed therapeutics digital MCMs host-based diagnostics lung therapeutics $500K+

Posted Nov 8, 2022

Due Oct 18, 2027

Description

The HHS BARDA DRIVe EZ-BAA (EZ-BAA-22-100-SOL-00003) solicits research and development proposals for advanced medical countermeasures, including areas of interest such as ReDIRECT, Lab at Home, Digital MCMs, Host-Directed Therapeutics, Healing Lungs, DRIVe Forward, Vaccines on Demand, ReBooT, Host-Based Diagnostics, and REPAIR. This reissuance supersedes prior versions and opens these specific AOIs with defined closing dates. Eligible bidders include biotech firms, academic researchers, and industry innovators specializing in pandemic preparedness, diagnostics, therapeutics, and vaccines.

A strong match for healthcare vendors

Curated for medical & healthcare suppliers

Why we classified this as medical

BARDA (Biomedical Advanced Research and Development Authority) under HHS is issuing a Broad Agency Announcement for medical countermeasures (MCMs) research areas like Digital MCMs, Host-Directed Therapeutics, Vaccines on Demand, and Healing Lungs, which directly target pharmaceuticals, vaccines, diagnostics, and therapeutics for public health emergencies. The AOIs explicitly focus on advanced medical product development, aligning with medical devices, pharmaceuticals, and lab diagnostics.

View Original Source

Save for Later

Send to Pipeline

Closing date unconfirmed

This bid lists a closing date of Oct 18, 2027, which is more than a year out — almost certainly a data error from the source. Treat the deadline as unknown.

Please confirm the actual deadline on the original source before you rely on it.

Check the source